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Abbreviations 
5-FU 
BBP 
5-fluorouracil 
Bevacizumab beyond progression 
CapeIRI Capecitabine plus  irinotecan 
CapeOx Capecitabine plus  oxaliplatin 
CI Confidence interval 
CRC Colorectal Cancer 
ECOG Eastern Cooperative Oncology Group 
EGFR Epidermal growth factor receptor 
EMA European Medicines Agency 
FDA U.S. Food and Drug Administration 
FOLFIRI Fluorouracil plus  leucovorin plus  irinotecan 
FOLFOX Fluorouracil plus  leucovorin plus  oxaliplatin 
FOLFOXIRI Fluorouracil plus  leucovorin plus  oxaliplatin plus  irinotec-
an 
HR Hazard ratio 
IFL 
IROX 
Irinotecan plus  leucovorin plus  fluorouracil 
Irinotecan plus  oxaliplatin 
ITT Intention-to-treat 
kg Kilogramme  
KRAS Kirsten rat sarcoma 
LV Leucovorin 
mCRC Metastatic colorectal cancer 
mg Milligramme  
ml Millilitre 
NRAS Neuroblastoma RAS viral oncogene homolog 
OS Overall survival 
PFS 
PFS1 
PFS2 
Progression-free survial 
PFS from randomisation to first progression 
PFS from randomisation to second progression 
RECIST Response Evaluation Criteria in Solid Tumours 
SEER Surveillance, Epidemiology and End Results 
TTP Time to progression 
TT2PD Time from randomisation to disease progression upon any 
treatment given after PFS1 
VEGF Vascular endothelial growth factor 
XELIRI Capecitabine plus  irinotecan 
XELOX Capecitabine plus  oxaliplatin 
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1 Drug description 
Generic/Brand name/ATC code:  
Bevacizumab/Avastin®/L01XC07 
Developer/Company:  
Roche Registration Ltd. 
Description:  
Bevacizumab (Avastin®) is a recombinant monoclonal antibody that binds to 
vascular endothelial growth factor (VEGF). By inhibiting VEGF receptor 
binding, bevacizumab prevents the growth and maintenance of tumour 
blood vessels [1]. 
Bevacizumab is used for the treatment of different types of cancer and in 
various combinations with other drugs. In patients with metastatic colorec-
tal cancer (mCRC) who have progressed on a first-line Avastin®-containing 
regimen, the drug is administered at a dosage of 5 mg/kg every two weeks or 
7.5 mg/kg every three weeks when used in combination with a fluoropyrimi-
dine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regi-
men. Patients receive Avastin® as an intravenous infusion; treatment should 
be continued until disease progression or unacceptable toxicity [2]. 
 
2 Indication 
Bevacizumab (Avastin®) can be used for patients with mCRC who have 
progressed on first-line Avastin®-containing regimen. It is administered in 
combination with fluoropyrimidine-irinotecan or fluoropyrimidine-
oxaliplatin based chemotherapy [2].   
 
3 Current regulatory status 
The EMA granted marketing authorisation for Avastin® in combination with 
fluoropyrimidine-based chemotherapy for the first-line treatment of adult 
patients with mCRC in 2005. The indication was extended subsequently and 
is no longer connected to specific lines of therapy. The indication of this as-
sessment was included in the Summary of Product Characteristics in May 
2013. 
The EMA approved Avastin® for the following further indications [3]: 
- first-line treatment of adult patients with metastatic breast cancer 
(combination with paclitaxel) 
- first-line treatment of adult patients with metastatic breast cancer 
in combination with capecitabine (when other chemotherapy op-
tions including taxanes or anthracyclines are not considered appro-
priate) 
bevacizumab inhibits 
growth and 
maintenance of tumour 
blood vessels 
 
 
intravenous 
administration 
indicated in patients 
who have progressed on 
first-line bevacizumab-
containing regimen 
approved by the EMA 
for all lines of therapy 
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- adult patients with unresectable, advanced, metastatic or recurrent 
non-small cell lung cancer (in addition to platinum-based chemo-
therapy) 
- first-line treatment of adult patients with advanced and/or meta-
static renal cancer (in combination with interferon alfa-2a) 
- front-line treatment of adult patients with advanced epithelial ovar-
ian, fallopian tube or primary peritoneal cancer (in combination 
with carboplatin and paclitaxel) 
- adult patients with first recurrence of platinum-sensitive epithelial 
ovarian, fallopian tube or primary peritoneal cancer who have not 
received prior therapy with bevacizumab or other VEGF inhibitors 
or VEGF receptor-targeted agents (in combination with carboplatin 
or gemcitabine). 
In February 2004, the FDA approved Avastin® for the first-line treatment of 
patients with mCRC for the use in combination with intravenous 5-
fluorouracil-based chemotherapy [4]. On 23 January 2013, the approval for 
bevacizumab was extended and is currently valid for: 
- patients with mCRC, combined with intravenous 5-fluorouracil-
based chemotherapy for first- or second-line treatment 
- as second-line treatment in combination with fluoropyrimidine-, 
irinotecan- or fluoropyrimidine-oxaliplatin based chemotherapy for 
patients with mCRC who have progressed on a first-line Avastin®-
containing regimen [4]  
- non-squamous non-small cell lung cancer (in combination with 
carboplatin and paclitaxel, for first-line treatment of unresectable, 
locally advanced, recurrent or metastatic disease) 
- glioblastoma in adult patients with progressive disease following 
prior therapy (used as single agent) 
- patients with metastatic renal cell carcinoma in combination with 
interferon alfa [4]. 
In November 2011 the FDA removed breast cancer indication from the 
Avastin® label. The decision was based on a lack of benefit concerning delay 
in the growth of tumours that would justify the potential risks. Furthermore, 
there is no evidence that Avastin® treatment lengthens life or improves the 
quality of life of women with breast cancer [5]. 
 
4 Burden of disease 
CRC develops in the tissues of the colon and/or rectum. 
Advanced CRC can be defined as a disease that 
- is metastatic at presentation of a patient 
- progresses to become metastatic or 
- is locally advanced in a way that its resectability is uncertain [6]. 
Incidence rates of CRC are declining, potentially also caused by increased use 
of screening tests. These tests allow the early detection and consecutive re-
moval of colorectal polyps before their progress to cancer [7]. In Austria, CRC 
is the third most common malignancy diagnosed in men and the second most 
indication approved by 
the FDA 
 
 
 
 
 
 
 
incidence rate in Austria 
26.8 per 100,000 per 
year 
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common malignancy diagnosed in women. In 2011, the incidence rate in Aus-
tria for both men and women was 26.8 (per 100,000 people per year), the mor-
tality rate was 11.7 (per 100,000 people per year) [8]. 
At the time of diagnosis, more than 90% of patients with CRC are older than 
50 years; the average age at diagnosis is 72 years [9]. The 1-year relative sur-
vival rate for patients with CRC is 83%, the 5-year relative survival rate is 65% 
(relative survival compares survival among cancer patients to that of people 
not diagnosed with cancer who are of the same age, race and sex). When de-
tected at a localised stage, the 5-year survival for patients with CRC is 90%, it 
declines to 70% when the tumour has spread to nearby organs or lymph nodes 
and to 13% in case of distant metastases [9].  
Histologically, more than 95% of CRCs are adenocarcinomas. Other, less 
common types are carcinoid tumours, gastrointestinal stromal tumours 
(GISTs), lymphomas or sarcomas [10]. 
Risk factors for the development of CRC are: 
- increasing age 
- hereditary and medical factors such as a personal or family history of 
CRC and/or polyps, a personal history of chronic inflammatory bow-
el disease, certain inherited genetic conditions and type 2 diabetes 
- modifiable factors: obesity, physical inactivity, a diet high in red or 
processed meat, alcohol consumption, long-term smoking, very low 
intake of fruit and vegetables [9]. 
In contrast, consumption of milk and calcium, and higher blood levels of vit-
amin D seem to decrease the risk for CRC [9]. 
Common symptoms of CRC are visible blood in the stool, abdominal pain, 
otherwise unexplained iron-deficiency anaemia and/or changes in bowel hab-
its. Less common symptoms are abdominal distension, and/or nausea and 
vomiting. Straining to defecate, rectal pain or small-calibre stools indicate that 
the tumour is located in the rectum. CRC is a potentially metastatic disease; 
the most frequently affected sites are the regional lymph nodes, the liver, the 
lungs and the peritoneum. Approximately 20% of patients have metastases at 
the time of diagnosis. The preferred staging system for CRC is the TNM clas-
sification: primary tumour (T), regional lymph node (N), distant metastasis 
(M) [11].  
 
5 Current treatment 
The recommended therapy options for patients with mCRC after progres-
sion on first-line therapy depend on previously administered therapies [10]: 
 
 
 
 
 
 
average age at the time 
of diagnosis: 72 years 
more than 95% of CRCs 
are adenocarcinomas 
therapy options for 
patients with mCRC 
after progression on 
first-line therapy 
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Initial treatment Recommended therapy options  
after progression of mCRC 
FOLFOX- or CapeOx-based 
regimen 
FOLFIRI or irinotecan alone or with cetuximab or pa-
nitumumab (KRAS/NRAS wild-type tumour only), 
bevacizumab or ziv-aflibercept 
FOLFIRI-based regimen FOLFOX or CapeOX alone or with bevacizumab, ce-
tuximab or panitumumab plus irinotecan; or single-
agent cetuximab or panitumumab (for patients not ap-
propriate for the combination with irinotecan) 
5-FU/LV or capecitabine with-
out oxaliplatin or irinotecan  
FOLFOX, CapeOx, FOLFIRI, single-agent irinotecan, 
or irinotecan plus oxaliplatin (IROX; less common); 
can be varyingly combined with bevacizumab or ziv-
aflibercept  
FOLFOXIRI Cetuximab or panitumumab plus irinotecan or cetuxi-
mab or panitumumab alone (patients with wild-type 
KRAS/NRAS) 
Abbreviations: FOLFOX = fluorouracil, leucovorin, oxaliplatin; CapeOx = capecitabine, oxali-
platin; FOLFIRI = fluorouracil, leucovorin, irinotecan; KRAS = Kirsten rat sarcoma; NRAS = 
neuroblastoma RAS viral oncogene homolog; 5-FU = 5-fluorouracil; LV = leucovorin; FOL-
FOXIRI = fluorouracil, leucovorin, oxaliplatin, irinotecan 
As a part of initial therapy, bevacizumab, panitumumab or cetuximab can 
be used; analysis within the SEER (Surveillance, Epidemiology and End Re-
sults) database showed that the addition of bevacizumab to first-line chemo-
therapy was associated with a small improvement in OS, whereas the risk for 
stroke and perforation (but not for cardiac events) was increased [12].  
The addition of bevacizumab continuation to second-line treatment options 
was included in the recommended therapy options in 2013. The VEGF in-
hibitor may be added to any regimen that does not contain an epidermal 
growth factor receptor (EGFR) inhibitor or ziv-aflibercept [10]. 
 
6 Evidence 
A literature search was conducted in April 2014 in four databases (Med-
line, Embase, CRD Database and The Cochrane Library). Search terms 
were “Colorectal Neoplasms”, “Bevacizumab”, “Avastin”, “Altuzan”, 
“nsc704865”, “Neoplasm Metastasis”. Also, the manufacturer was contact-
ed for any further evidence, and submitted 2 references (both already iden-
tified by the systematic literature search) and information about 1 trial 
(CAIRO3, results not published yet, see 6.1). 
Overall, 810 references were identified. Included in this report are: 
- 2 phase III studies, assessing continued use of bevacizumab plus 
standard second-line chemotherapy in patients with mCRC pro-
gressing after standard first-line bevacizumab-based treatment [12, 
13]. 
- 4 phase II studies and 2 observational cohort studies, described in 
6.2.
2 phase III studies,  
4 phase II and  
2 observational cohort 
studies were included 
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6.1 Efficacy and safety – phase III studies 
6.1.1 NCT00700102 
Table 1: Summary of efficacy 
Study title  
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a 
randomised phase III trial [12]. 
Study  
identifier 
NCT00700102, EudraCT Number 2006-004634-32 
Design Prospective, intergroup, randomised (1:1 ratio), open-label, multicentre (220 centres in 
15 countries) 
Duration  Enrolment: 2006-02-01 to 2010-06-09 
Median follow-up: 11.1 months (bevacizumab plus chemotherapy 
group), 9.6 months (chemotherapy alone group) 
Cut-off dates for analyses: 2011-05-31 
Hypothesis Superiority  
The study was designed to detect a 30% (hazard ratio 0.77) improvement in median 
overall survival with 90% power, assuming a two-sided 5% type 1 error and median 
overall survival for chemotherapy alone of 10 months. 
Funding F. Hoffmann-La Roche 
Treatment 
groups 
Intervention 
(n=409) 
Second-line chemotherapy (infusional or bolus fluorouracil or 
oral capecitabine plus irinotecan or oxaliplatin) plus  
Bevacizumab at 2.5 mg/kg per week equivalent (either 5 mg/kg 
intravenously every two weeks or 7.5 mg/kg every 3 weeks 
intravenously)  
Control 
(n=411) 
Second-line chemotherapy (infusional or bolus fluorouracil or 
oral capecitabine plus irinotecan or oxaliplatin) 
Endpoints 
and 
definitions 
Overall survival 
(primary outcome) 
OS Time from randomisation to death from any cause 
Progression-free 
survival 
PFS Time from randomisation to documented disease 
progression or death from any cause 
Overall survival 
from the start of 
first-line treatment 
- Time from the start of first-line treatment to death from 
any cause 
Confirmed best 
overall response 
- Assessed with modified Response Evaluation Criteria in 
Solid Tumours (RECIST, version 1.0) 
Safety - Adverse events, laboratory data 
On-treatment 
progression-free 
survival 
- Time from randomisation to documented disease 
progression or death from any cause only if occurred up 
to 28 days after the last confirmed dose of study 
treatment 
Exploratory 
endpoints 
- Evaluation of OS, PFS and subsequent anticancer 
treatments according to KRAS mutation status  
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Results and analysis 
Analysis  
description 
Intention-to-treat analysis 
Overall survival curves were estimated with the Kaplan-Meier method 
Primary analysis was done with unstratified log-rank tests 
Unstratified Cox regression models were used to estimate the HR for OS, unstratified 
log-rank tests were used to assess differences 
Unstratified log-rank tests were used for analysis of PFS, PFS on treatment and OS 
from the start of first-line treatment 
Cox regression models were used to generate HRs 
Unstratified Cox regression models were used to generate HRs and corresponding 95% 
CIs for all secondary endpoints, subgroup analysis and the exploratory analysis by KRAS 
status 
Unstratified χ2 tests were used to assess between-groups differences for best overall 
response and post-hoc analysis of disease control 
Analyses were done with SAS (version 8.2) 
Analysis  
population 
Inclusion  Age ≥ 18 years 
 Histologically confirmed, measurable mCRC 
 ECOG performance status 0–2 
 Tumour disease according to RECIST by investigator up to 4 
weeks prior to start of study treatment 
 Previous treatment with bevacizumab plus standard first-line 
chemotherapy including a fluoropyrimidine plus either 
oxaliplatin or irinotecan  
 Not appropriate for primary metastasectomy 
Exclusion  Progressive disease for more than 3 months after the last 
bevacizumab administration  
 First-line PFS of less than 3 months 
 Less than 3 months (consecutive) of first-line bevacizumab 
Characteristics  Intervention Control 
 Sex, % 
Male/female 
 
65/35 
 
63/37 
Median age, years 63 63 
ECOG performance 
status, % 
0/1/2 
                     
 
44/51/5 
 
 
43/52/5 
First-line PFS, 
months 
≤9/>9 
 
54/46 
 
56/44 
Liver metastasis 
only, % 
No/yes 
 
73/27 
 
71/29 
Number of organs 
with metastases, % 
≤1/>1 
 
36/64 
 
39/61 
Time from last 
bevacizumab dose, 
days 
≤42/>42 
 
 
77/23 
 
 
77/23 
First-line 
chemotherapy, % 
Irinotecan-based 
Oxaliplatin-based 
 
 
59 
41 
 
 
58 
42 
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Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Intervention  
(Bevacizumab plus  
chemotherapy) 
Control  
(chemotherapy alone) 
Number of subjects N=409 N=411 
OS  
Median (95% CI), months 
 
11.2 (10.4–12.2) 
 
9.8 (8.9–10.7) 
PFS 
Median (95% CI), months 
 
5.7 (5.2–6.2) 
 
4.1 (3.7–4.4) 
OS from the start of first-
line treatment 
Median (95% CI), months 
 
23.9 (22.2–25.7) 
 
22.5 (21.4–24.5) 
PFS on treatment 
Median (95% CI), months 
 
5.7 (5.2–6.2) 
 
4.0 (3.7–4.3) 
 Number of subjects N = 404 N = 406 
Tumour response, number 
(%) 
Complete response 
Partial response 
Stable disease 
Progressive disease 
Missing or not 
assessable 
 
1 (<1) 
21 (5) 
253 (63) 
87 (22) 
42 (10) 
 
2 (<1) 
 14 (3) 
 204 (50) 
 142 (35) 
44 (11) 
Effect 
estimate per 
comparison 
Comparison groups  Intervention vs Control 
OS HR 0.81 
95% CI 0.69–0.94 
P value  0.0062 
PFS HR 0.68 
95% CI 0.59–0.78 
P value <0.0001 
OS from the start of first-
line treatment 
HR 0.90 
95% CI 0.77–1.05 
P value  0.17 
PFS on treatment HR 0.63 
95% CI 0.53–0.74 
P value  <0.0001 
Confirmed response HR NR 
95% CI NR 
P value 0.31 
  Disease control HR NR 
95% CI NR 
P value  <0.0001 
Abbreviations: CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; KRAS = Kirsten 
rat sarcoma; NCT = National Clinical Trial; NR = not reported; OS = overall survival; PFS = progression-free survival; 
RECIST = Response Evaluation Criteria in Solid Tumours 
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Table 2: Most frequent adverse events (occurring in 2% or more of patients, safety population) 
Adverse Event (according  
to NCI-CTC version 3.0) 
Bevacizumab plus  
chemotherapy 
(N=401) 
Chemotherapy alone 
(N=409) 
Grade 3–5, n (%)   
Neutropenia 65 (16) 52 (13) 
Leucopenia 16 (4) 12 (3) 
Asthenia 23 (6) 17 (4) 
Fatigue 14 (3) 10 (2) 
Diarrhoea 40 (10) 34 (8) 
Vomiting 14 (3) 13 (3) 
Nausea 13 (3) 11 (3) 
Decreased appetite 5 (1) 9 (2) 
Mucosal inflammation 13 (3) 4 (1) 
Abdominal pain 15 (4) 12 (3) 
Polyneuropathy 12 (3) 6 (1) 
Peripheral neuropathy 5 (1) 10 (2) 
Hypokalaemia 9 (2) 8 (2) 
Dyspnoea 6 (1) 12 (3) 
Pulmonary embolism 10 (2) 8 (2) 
Hypertension 7 (2) 5 (1) 
Bleeding or haemorrhage 8 (2) 1 (<1) 
Venous thromboembolic events 19 (5) 12 (3) 
Gastrointestinal perforation 7 (2) 3 (<1) 
Subileus 8 (2) 2 (<1) 
Other   
Treatment discontinuation  
due to adverse events: 
  
Discontinuation of any treatment 63 (16) 36 (9) 
Discontinuation of chemotherapy only or 
chemotherapy plus  bevacizumab 
53 (13) NR 
Discontinuation of bevacizumab 10 (2) – 
Deaths not related to PD 23 (6) 22 (5) 
Abbreviations: NCI = National Cancer Institute; n = number; CTC = Common Toxicity Criteria; NR = not reported; PD 
= progressive disease 
 
 
This phase III study was conducted to assess the continued use of bevaci-
zumab plus standard second-line therapy in 820 patients with mCRC who 
have progressed after a standard first-line bevacizumab-containing regimen. 
Patients were randomly assigned in a 1:1 ratio to two treatment arms: 50% 
(N=409) of patients received bevacizumab plus chemotherapy and 50% 
(N=411) received chemotherapy alone. At the investigator’s discretion, pa-
tients were treated with infusional or bolus fluorouracil or oral capecitabine 
plus irinotecan or oxaliplatin, with or without bevacizumab at 2.5 mg/kg per 
week equivalent (either 5 mg/kg intravenously every two weeks or 7.5 mg/kg 
intravenously every three weeks). The type of second-line chemotherapy de-
the continued use of 
bevacizumab plus 
standard second-line 
therapy was assessed in 
820 patients 
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pended on the first-line regimen (switch of chemotherapy). At the discretion 
of the physician several different chemotherapy regimens were applied as 
second-line therapy (e.g. FOLFIRI, FOLFOX, XELOX). Treatment was 
continued until progression of disease, patient’s refusal to continue or occur-
rence of unacceptable toxicity. 
All patients had previously been treated with bevacizumab plus standard 
first-line chemotherapy including a fluoropyrimidine plus either oxaliplatin 
(41% bevacizumab plus chemotherapy group vs. 42% chemotherapy alone 
group) or irinotecan (59% bevacizumab plus chemotherapy group vs. 58% 
chemotherapy alone group). Patients in both groups had a median age of 63 
years and an ECOG performance status of 0–2. 64% of patients (bevaci-
zumab plus chemotherapy group) and 61% (chemotherapy alone group) had 
more than one organ with metastases.  
Median duration of treatment with bevacizumab was 3.9 months; median 
overall treatment exposure was 4.2 months in the bevacizumab plus chemo-
therapy group compared to 3.2 months in the chemotherapy alone group. 
After study treatment was completed, 69% (bevacizumab plus chemotherapy 
group) and 68% of patients (chemotherapy alone group) received one or 
more subsequent anticancer treatments.  
The primary endpoint of this trial was OS; secondary endpoints were PFS, 
OS from the start of first-line treatment, confirmed best overall response and 
safety, and on-treatment PFS as an additional secondary endpoint. As ex-
ploratory endpoints, evaluation of OS, PFS and subsequent anticancer 
treatments according to the KRAS mutation status were mentioned. 
Median OS was 11.2 months (95% CI 10.4–12.2) in the bevacizumab plus 
chemotherapy group compared to 9.8 months (8.9–10.7) in the chemothera-
py alone group (HR 0.81, 95% CI 0.69–0.94; p=0.0062). In the bevacizumab 
plus chemotherapy group, median PFS was 5.7 months (95% CI 5.2–6.2) 
compared to 4.1 months (95% CI 3.7–4.4) in the chemotherapy group (HR 
0.68, 95% CI 0.59–0.78; p<0.0001). A confirmed response, primarily partial 
responses, in patients with one or more measurable lesions at baseline was 
achieved by 5% in the bevacizumab plus chemotherapy group and by 4% of 
patients in the chemotherapy alone group (unstratified χ2 test p=0.31).  
The retrospectively documented median OS from the start of first-line 
treatment was 23.9 months (95% CI 22.2–25.7) in the bevacizumab plus 
chemotherapy arm compared to 22.5 months (21.4–24.5) in the chemothera-
py alone arm (HR 0.90, 95% CI 0.77–1.05; unstratified log-rank p=0.17). 
Analysis of the median PFS on treatment showed the following results: 5.7 
months (95% CI 5.2–6.2) in the bevacizumab plus chemotherapy group and 
4.0 months (95% CI 3.7–4.3) in the chemotherapy alone group (HR 0.63, 
95% CI 0.53–0.74; unstratified log-rank p<0.0001). 
Adverse events occurred in 98% (bevacizumab plus chemotherapy group) 
and 99% (chemotherapy alone group) of patients. 64% of patients in the 
bevacizumab plus chemotherapy arm and 57% of the chemotherapy alone 
arm showed grade 3–5 adverse events. The most common grade 3–5 adverse 
events were neutropenia, diarrhoea and asthenia. In total, 11 grade 5 adverse 
events (resulting in death) were reported in each group. 4 of those deaths in 
the bevacizumab plus chemotherapy group and 3 in the chemotherapy alone 
group were deemed to be treatment-related; they were caused by upper gas-
trointestinal haemorrhage, cerebrovascular accident, sudden death and neu-
tropenia (bevacizumab plus chemotherapy arm), intestinal perforation, gen-
all patients had prior 
bevacizumab treatment 
plus first-line 
chemotherapy  
median age of patients 
was 63 years, EGOG 
performance status was 
0–2 
OS extended by  
1.4 months and  
PFS by 1.6 months 
high rates of adverse 
events in both 
treatment arms 
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eral physical health deterioration and acute prerenal failure (chemotherapy 
alone arm). Serious adverse events were reported in 32% of patients in the 
bevacizumab plus chemotherapy group and in 33% of patients in the chemo-
therapy alone group. 
16% of patients (bevacizumab plus chemotherapy) and 9% of patients 
(chemotherapy alone group) discontinued treatment due to the occurrence 
of adverse events. In the bevacizumab plus chemotherapy arm, 13% of pa-
tients discontinued chemotherapy or both chemotherapy and bevacizumab 
because of adverse events and 2% of patients discontinued bevacizumab 
treatment due to adverse events. According to the study protocol, a dose re-
duction of bevacizumab during the study was not allowed. 
Additionally, an exploratory analysis evaluating outcomes according to tu-
mour Kirsten rat sarcoma virus oncogene (KRAS) status was conducted. 
Thereby, no apparent effect of tumour KRAS mutational status on the effi-
cacy of second-line bevacizumab in study patients has been shown, which 
means that bevacizumab beyond first progression is an option for patients 
with mCRC, independent of their KRAS-status [14].  
 
6.1.2 NCT00442637 
The manufacturer of Avastin® provided information about CAIRO3, a ran-
domised, multicentre, open-label phase III study [13]. Results are not yet 
fully published, but final results were presented at ASCO 2014. 558 patients 
with previously untreated mCRC received six cycles of induction therapy 
with bevacizumab plus XELOX and were then randomised either to arm A 
(observation, N=279) or to arm B (bevacizumab plus capecitabine, N=279). 
After first progression of disease, patients of both groups received bevaci-
zumab plus XELOX until second progression. Primary endpoint of the 
study was PFS2 (= PFS from randomisation to second progression), second-
ary endpoints were PFS1 (= PFS from randomisation to first progression), 
OS, TT2PD (= time from randomisation to disease progression upon any 
treatment given after PFS1), overall response rate and safety. Median follow-
up was 48 months; the cut-off date was 2014-01-06.  
Median PFS2 was 11.7 months in arm B versus 8.5 months in arm A (HR 
0.67, 95% CI, 0.56–0.81, p<0.0001). Analysis showed that median PFS1 sig-
nificantly improved with maintenance of bevacizumab plus capecitabine 
(8.5 months) versus observation (4.1 months), resulting in stratified HR 0.43 
(95% CI, 0.36–0.52, p<0.0001). After first progression, bevacizumab plus 
XELOX was reintroduced in 60% of patients in arm A and in 47% in arm B 
[15]. Median TT2PD was 13.9 months in the maintenance treatment group 
compared to 11.1 months in the observation group (HR 0.68, 95% CI, 0.57–
0.82, p<0.0001). In contrast, there was a non-significant benefit in median 
OS for ITT (intention-to-treat) population: 21.6 months in the maintenance 
group, 18.1 months in the observation group (HR 0.89, 95% CI, 0.73–1.07, 
p=0.22). Furthermore, despite statistically significant differences favouring 
the observation group, results on quality of life did not show a clinically rel-
evant difference. The authors concluded that quality of life was preserved in 
patients treated with maintenance (bevacizumab plus capecitabine) therapy. 
CAIRO3 evaluated the 
use of maintenance 
bevacizumab plus 
capecitabine after 
induction with 
bevacizumab plus 
XELOX 
significant benefit in 
PFS1 and TT2PD 
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6.2 Efficacy and safety – further studies 
Assessing the timing (first-line or later use) of bevacizumab in the overall 
treatment of advanced mCRC was the aim of this phase II study [16]: 41 pa-
tients (median age was 61 years) who progressed after first-line therapy of 5-
fluorouracil, oxaliplatin-/irinotecan-based regimens with (19 patients) or 
without bevacizumab (22 patients) were randomised to receive second-line 
therapy consisting of either chemotherapy plus bevacizumab or chemother-
apy alone (FOLFOX or FOLFIRI). Of the 19 patients who had progressed 
on bevacizumab containing first-line therapy, 7 received second-line therapy 
with chemotherapy plus bevacizumab. Partial response was 25% (second-
line bevacizumab group) and 18.8% (patients with first-line chemotherapy 
and bevacizumab-based regimen) compared to 11.8% and 5.9% with second-
line chemotherapy. TTP (median time to progression) was 3.1 months com-
pared to 2.3 months in patients with first-line chemotherapy and bevaci-
zumab-based regimens respectively. Median survival was 8.2 versus 4 
months in both groups. Adverse events were not statistically significant be-
tween bevacizumab with or without chemotherapy, but cardiovascular 
events such as hypertension or bleeding occurred only in the combination 
group.  
The SILK study [17], a phase II trial, evaluated the efficacy and safety of 
bevacizumab beyond progression (BBP) for patients with mCRC who pro-
gressed on first-line chemotherapy plus bevacizumab. Therefore, 39 patients 
received either FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab, 
depending on the previous first-line regimen. Median age of patients was 62 
years, all had confirmed disease progression and had received a combination 
of bevacizumab and FOLFOX or FOLFIRI as first-line therapy. The overall 
response rate (primary endpoint) was 16.2%; disease control rate was 76%. 
Median OS was 417 days, median PFS was 150 days and total survival from 
initiation of first-line treatment was 988 days. Safety analysis showed that 
fatigue (23%), hypertension (18%), diarrhoea (10%), vomiting (5%) and an-
orexia (5%) were the most common non-haematological grade 3 or 4 adverse 
events, whereas neutropenia (33%), leucopenia (13%), febrile neutropenia 
(13%) and haemoglobin decrease (8%) were the most common grade 3 or 4 
haematological toxic events.  
Another prospective, open-label, multicentre phase II study conducted in 
Korea [18] evaluated the efficacy and safety of BBP combined with doublet 
chemotherapy in patients with mCRC. The study included 76 patients who 
received second-line continuation of bevacizumab (5 mg/m² every two weeks 
when 5-FU-based regimen was used or 7.5 mg/m² every three weeks when 
combined with capecitabine-based regimen) plus switched doublet chemo-
therapy consisting of FOLFOX, CapeOx or FOLFIRI. Patients had a medi-
an age of 57 years and the ECOG performance status was 0–1. 52.6% of pa-
tients had received CapeOx, 22.4% FOLFOX, 17.1% FOLFIRI and 7.9% re-
ceived CapeIRI (capecitabine plus irinotecan) as first-line chemotherapy 
(plus bevacizumab). Patients with disease progression after first-line 
FOLFIRI or CapeIRI (plus bevacizumab) received FOLFOX or CapeOx, 
those who had first-line FOLFOX or CapeOx (plus bevacizumab) subse-
quently received FOLFIRI. The treatment was given until the occurrence of 
disease progression, unacceptable toxicity or patient refusal. After a median 
follow-up of 12.3 months, median PFS was 6.5 months (95% CI, 5.2–7.8), 
median OS was 12.8 months (95% CI, 8.8–16.9) and no significant differ-
phase II study evaluated 
the timing of 
bevacizumab in 41 
patients 
SILK study assessed the 
efficacy and safety of 
BBP in 39 patients 
Korean study 
investigated the efficacy 
and safety of BBP 
combined with doublet 
chemotherapy in 76 
patients 
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ences according to combined chemotherapy were established. Regarding the 
overall response rate of 17.1% (95% CI, 8.6–25.6), the majority of responses 
were stable disease with complete responses in 2 patients and partial re-
sponses in 11 patients. Bevacizumab-related adverse events of grade 3 or 4 
were proteinuria (1.3% of patients) and thromboembolism (1.3% of pa-
tients). 
The aim of a phase II, multicentre, single-arm study [19] was to investigate 
the efficacy and safety of BBP in Japanese patients with mCRC. Therefore, 
47 patients (median age 63 years) initially received bevacizumab (5 mg/kg) 
plus FOLFOX6 until tumour progression. Subsequently, 31 patients re-
ceived bevacizumab plus FOLFIRI for second-line therapy. The primary 
endpoint of the trial, the 2nd PFS (duration from enrolment until progres-
sion after second-line therapy), was 18.0 months (95% CI, 13.7–22.3 
months). The median OS was 30.8 months (95% CI, 27.7–34.0 months), me-
dian survival beyond first progression was 19.6 months (95% CI, 13.5–25.7 
months), the response rate was 29.0%, the disease control rate was 64.5% 
and median PFS from initiation of second-line therapy was 7.3 months (95% 
CI, 5.0–9.6 months). Haematologic and non-haematologic adverse events 
grade >3 occurred in 44.4% and 16.7% respectively. Bevacizumab-
associated toxicity (>grade 3) occurred in 2.1% of patients receiving first-
line therapy (gastrointestinal perforation) and in 3.2% of patients receiving 
second-line therapy (hypertension).  
A frequently cited study is BRiTE (Bevacizumab Regimens: Investigation of 
Treatment Effects and Safety) [20], a prospective observational cohort 
bevacizumab treatment study. 1,953 patients were enrolled; previously un-
treated patients and patients with first-line treatment with bevacizumab 
were included. More than half of the patients (55.9%) had received FOL-
FOX for first-line chemotherapy. The median age of patients at baseline was 
63 years, and the majority (>80%) had an ECOG performance status of 0 or 
1. At a median follow-up of 19.6 months, 1,445 patients experienced first 
progression and were then classified into three groups according to the 
treatment they had received: no treatment, post-disease progression treat-
ment without bevacizumab and post-disease progression treatment with 
bevacizumab. Post-progression treatment could include any systemic anti-
cancer therapy (cytotoxic and/or biologic agents as well) at the discretion of 
the physician. Overall, 642 patients received bevacizumab mainly at a dos-
age of 5 mg/kg every two weeks (90.7%). Of these, 69.2% had received 
bevacizumab continuously beyond progression or restarted the therapy with-
in 1 month, whereas 30.8% had discontinued bevacizumab before progres-
sion or at first progression and restarted more than 1 month after first pro-
gression. OS and survival beyond first progression showed better outcomes 
for patients who had received bevacizumab after first progression (median 
OS 31.8 months, median survival beyond first progression 19.2 months) in 
comparison to patients without any further therapy (median OS 12.6 
months, survival beyond first progression 3.6 months) or those not receiving 
bevacizumab (median OS 19.9 months, survival beyond first progression 9.5 
months). Results for time to progression were similar across the three 
groups. When patients were analysed according to the time-lag (i.e. >2 
months) of initiation of further therapy after disease progression, patients 
receiving bevacizumab within 2 months of disease progression had an even 
greater improvement in OS than those who had not received bevacizumab 
beyond first progression. The most common adverse event was new or wors-
ened hypertension: 19.0% (no post-disease progression treatment), 19.2% 
evaluation of efficacy 
and safety of BBP in 47 
Japanese patients 
BRiTE study: large-scale 
observational cohort 
study  
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(post-disease progression treatment without bevacizumab) and 24.6% 
(bevacizumab beyond first progression) of patients were affected.  
Another prospective, multicentre, observational cohort study is ARIES: 
Avastin® Registry – Investigation of Effectiveness and Safety [21]. Patients 
receiving bevacizumab in combination with either first- or second-line 
chemotherapy were enrolled. 482 patients were enrolled in the second-line 
setting. Median age was 62 years and only 8.6% had ECOG PS ≥2. Chemo-
therapy in the second-line setting was at the discretion of the physician, but 
the most commonly administered regimens were FOLFOX and FOLFIRI. 
210 patients had received bevacizumab as first-line therapy, whereas 272 
were bevacizumab-naïve. At a median follow-up of 16.9 months, PFS was 7.6 
for bevacizumab-exposed patients in comparison to 8.1 months for bevaci-
zumab-naïve patients. For OS, measured from the beginning of the second-
line therapy, the corresponding numbers were 19.8 months and 17.2 months. 
Adverse events occurred in 16.4% of patients, of which 6.8% were serious. 
Adverse events were comparable between bevacizumab-naïve and exposed 
patients, with the exception of 4 deaths (1.5%) due to adverse events in the 
bevacizumab-exposed group in comparison to no deaths in the naïve group.  
 
7 Estimated costs 
The dosage schedule for Avastin® maintenance therapy in patients with 
mCRC who have progressed after first-line Avastin®-containing therapy is 5 
mg/kg every two weeks or 7.5 mg/kg every three weeks (intravenously) when 
used in combination with a fluoropyrimidine-irinotecan or fluoropyrimi-
dine-oxaliplatin based regimen [4]. Bevacizumab (Avastin®) is available in 
vials of 4 ml (25 mg/ml) at € 414.05 and vials of 16 ml (25 mg/ml) at € 
1,421.9 [22]. 
Assuming a body weight of 70 kg and median treatment duration of four 
months (median treatment duration in ML18147 trial was 3.9 months [12]), 
total costs for bevacizumab maintenance treatment are approximately € 
11,375.2 (monthly costs: € 2,843.8). Additionally, costs for first-line bevaci-
zumab, chemotherapeutical regimens and the management of adverse events 
incur. 
 
8 Ongoing research 
In May 2014, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted; the following trials were identi-
fied: 
 NCT00973609 (EudraCT Number 2008-007797439): A randomised, 
three-arm phase III study evaluating the efficacy of maintenance 
and reinduction treatment or no treatment and watchful waiting in 
patients with inoperable or irresectable and non-progressive meta-
static CRC after first-line induction treatment for 24 weeks with 
fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemother-
apy. The estimated study completion date is December 2015. 
ARIES study: 
investigating the 
combination of 
bevacizumab with first- 
or second-line therapy  
monthly costs for 
bevacizumab 
maintenance treatment: 
approx. € 2,843.8 
various ongoing phase 
III and phase IV trials 
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 NCT00544700: This phase III trial aims to evaluate the efficacy of 
bevacizumab as maintenance therapy in patients with CRC after 
first-line therapy. Comparators are bevacizumab maintenance ther-
apy versus no anti-tumour treatment until progression. The esti-
mated study completion date is December 2017. 
 NCT01588990: An open-label, prospective, single-arm, phase IV 
study evaluating the markers of inflammation and PFS in patients 
with previously untreated mCRC. The study is conducted in two 
phases, phase A treatment (XELOX plus bevacizumab or mFOL-
FOX6 plus  bevacizumab) until first disease progression and phase 
B treatment (FOLFIRI plus bevacizumab) until second disease 
progression. The estimated study completion date is August 2016. 
 NCT01912443: An observational study that aims to assess the safety 
profile of bevacizumab in combination with chemotherapy in pa-
tients with mCRC (unlimited line of treatment). Estimated study 
completion date is August 2017. 
 NCT00952029: A randomised phase III trial evaluating the efficacy 
of FOLFIRI plus bevacizumab followed by combination chemo-
therapy with or without bevacizumab in patients with mCRC. Es-
timated study completion date is July 2016. 
 NCT01996306: A multinational, randomised phase III trial as-
sessing the effect of XELIRI with or without bevacizumab com-
pared with FOLFIRI with or without bevacizumab as second-line 
therapy in patients with mCRC. Estimated study completion date 
is January 2017. 
 NCT00720512: (EudraCT Number 2007-002886-11): An open-label, 
multicentre, randomised phase III study of second-line chemother-
apy with or without bevacizumab in patients with mCRC after first-
line chemotherapy with bevacizumab. Study completion date was 
March 2014; there are no results available yet. 
 NCT01878422: (EudraCT Number 2007-004539-44): A randomised, 
prospective, multicentre study (phase III) assessing the role of new 
target molecules with chemotherapy in first- and second-line 
treatment of mCRC. Patients receive chemotherapy with or without 
bevacizumab as first-line therapy followed by chemotherapy alone 
or chemotherapy plus bevacizumab with or without cetuximab as 
second-line therapy. Primary completion date is March 2014 
There are several trials ongoing, evaluating the use of bevacizumab for vari-
ous indications and different diseases.  
 
9 Commentary 
In 2013, the FDA approved second-line therapy with bevacizumab (Avas-
tin®) for patients with mCRC who have progressed on a first-line bevaci-
zumab-containing regimen, for the use in combination with fluoropyrimi-
dine-, irinotecan- or fluoropyrimidine-oxaliplatin based chemotherapy [4]. 
The EMA had initially approved bevacizumab in combination with fluoro-
pyrimide-based chemotherapy for the first-line therapy of mCRC, but spe-
cifically incorporated the results of the ML18147 trial in May 2013.  
Based on the positive results of 2 large observational studies, the BRiTE and 
the ARIES studies, continued use of bevacizumab beyond first progression 
approved by the EMA 
and the FDA 
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became of interest as a treatment option for mCRC patients [20, 21]. In line 
with this development, a pivotal ML18147 trial was published in 2013 [12] 
and first results of a second phase III trial (CAIRO3) have recently been 
published as an abstract [13]. Several phase II studies provide further data 
in support of this hypothesis.  
The ML18147 trial [12], a prospective, randomised, open-label phase III 
study, evaluated the continued use of bevacizumab plus standard second-
line chemotherapy in patients with mCRC who had progressed after stand-
ard first-line bevacizumab-based treatment. 820 patients were randomly as-
signed to two treatment arms. They received either chemotherapy plus 
bevacizumab (N=409) or chemotherapy alone (N=411). Median duration of 
treatment with bevacizumab was 3.9 months. All patients were previously 
treated with bevacizumab plus standard first-line chemotherapy, including 
fluoropyrimidine plus either oxaliplatin or irinotecan.  
Analyses showed a gain in median OS of 1.4 months for the bevacizumab 
plus chemotherapy group compared to the chemotherapy alone group. For 
median PFS a risk reduction of 32% was observed, also favouring the com-
bination regimen. Median OS from the start of first-line treatment was pro-
longed by 1.4 months in the bevacizumab plus chemotherapy arm compared 
to the chemotherapy alone arm.  
High rates of adverse events were observed in both treatment arms: 98% 
(bevacizumab plus chemotherapy group) and 99% of patients (chemothera-
py alone group) had adverse events. Grade 3–5 adverse events occurred in 
64% (bevacizumab plus chemotherapy) and 57% (chemotherapy alone) of 
patients. From overall 11 grade 5 adverse events resulting in death, 4 deaths 
in the bevacizumab plus chemotherapy group and 3 in the chemotherapy 
alone group were deemed to be treatment-related. Serious adverse events 
were similar in the two groups, which confirms the safety observations made 
in the BRiTE study [20], where only a higher incidence of new or worsened 
hypertension was observed; a fact that the authors attributed to the pro-
longed treatment exposure to bevacizumab. 
Preliminary published results from the CAIRO3 study demonstrate that 
administering maintenance treatment with capecitabine plus bevacizumab 
after induction therapy with bevacizumab, capecitabine and oxaliplatin sig-
nificantly prolonged time to disease progression in comparison to observa-
tion only by 4.4 months [13]. The time from randomisation to progression 
after the reintroduction of XELOX was extended by 3.2 months. OS did not 
reach a statistically significant difference.  
Even though these results indicate that maintenance therapy with bevaci-
zumab therapy adds some benefit after first disease progression, several 
questions remain unanswered. 
Firstly, median age of patients in the ML18147 trial in both treatment arms 
was 63 years and the majority of patients (95% in each group) had a good 
performance status (ECOG 0–1). Considering these facts, the applicability 
of study results to a clinical setting is questionable, since affected patients 
often are at a higher age (the average age at diagnosis of patients with 
mCRC is 72 years) [22]. However, a phase II study indicates that XELOX 
combined with bevacizumab is effective and its tolerability profile is man-
ageable when administered to elderly people (median age of study popula-
tion was 74 years) [23].  
ML18147 trial:  
OS increased by  
1.4 months 
median age of 63 years 
and good performance 
status of study 
population: applicability 
of results is questionable 
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Secondly, there is no single standard first-line therapy for the treatment of 
mCRC. Commonly used regimens are chemotherapy doublets using iri-
notecan (FOLFIRI) or oxaliplatin (e.g. FOLFOX, XELOX) as backbone. 
Even though recommendations concerning first-line therapy mention that 
bevacizumab can be added to commonly used first-line therapies, evidence 
for an additional benefit is scarce and improvements are limited [10, 24, 25]. 
A more pronounced benefit was derived when bevacizumab was added to 
“weaker” chemotherapy regimens not routinely used in the first-line setting 
of patients appropriate for intensive therapy such as FU/LV or bolus IFL 
(irinotecan plus  leucovorin plus  fluorouracil) [25, 26]. Therefore, incorpo-
rating bevacizumab first-line therapy, followed by bevacizumab mainte-
nance therapy as the standard approach for the treatment of all mCRC pa-
tients remains questionable.  
It should also be mentioned that the ML18147 trial excluded patients who 
had a first-line PFS of less than 3 months or those who did not receive the 
drug for more than 3 consecutive months. Therefore patients more likely to 
benefit from bevacizumab and those more likely to tolerate bevacizumab 
were included in this trial [27]. Furthermore, there is no clear distinction 
between second-line therapy and maintenance therapy with bevacizumab, a 
fact reflected in the inclusion criteria for the studies available. Patients were 
included up to less than 1–3 months after the last bevacizumab administra-
tion [12, 18, 20], they received bevacizumab continuously beyond progres-
sion [20], or no detailed information was provided for the time to initiation 
of second-line treatment [13, 19, 21]. Since analyses showed that cumulative 
exposure to bevacizumab after progression of disease is associated with in-
creased post-progression survival in patients with mCRC [28, 29] and sub-
group analyses indicate improved outcomes for patients receiving bevaci-
zumab within up to 2 months after first progression or the last bevacizumab 
administration, a clear definition of treatment lines (as described by Abrams 
et al. [29]) needs to be determined, most notably a precise distinction be-
tween maintenance therapy and second-line therapy.   
In addition to high costs associated with prolonged bevacizumab therapy, al-
ternative treatment options including EGFR inhibitors (e.g. cetuximab and 
panitumumab) or VEGF inhibitors (e.g. aflibercept or regorafenib) may 
yield better outcomes. Thus the application of different VEGF inhibitors or 
EGFR inhibitors for maintenance treatment should be taken into considera-
tion. For example, even though exploratory subgroup analyses from 
ML18147 did not show a difference in treatment effect in correlation with 
KRAS mutational status, preliminary results indicate better outcomes for 
KRAS wild-type mCRC for cetuximab (anti-EGFR) than for bevacizumab 
[30]. Positive results for continued VEGF inhibition were also presented for 
regorafenib, another VEGF inhibitor, in the CORRECT trial [31]. Findings 
about nintedanib, a small molecule angiokinase inhibitor with the ability to 
overcome different resistance mechanisms, might also be of interest [32]. 
Besides the optimal timing and duration of bevacizumab therapy, another 
issue concerns the optimal dosage of bevacizumab – with all factors impact-
ing on the costs. In this respect, the results of the EAGLE study [33] will be 
of peculiar interest: the multicentre, randomised phase III study aims to as-
sess the efficacy of the appropriate dose of bevacizumab (5 mg/kg or 10 
mg/kg) with FOLFIRI in patients with advanced or metastatic CRC who 
have failed prior bevacizumab plus oxaliplatin-based chemotherapy.   
no single standard first-
line therapy for mCRC 
treatment 
inclusion of patients 
more likely to benefit 
from bevacizumab in 
ML18147 trial 
use of EGFR or VEGF 
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considered 
EAGLE study (ongoing) 
evaluates appropriate 
dose of bevacizumab 
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In addition to the financial impact of prolonged bevacizumab therapy, side 
effects associated with long-term therapy are unknown. Foremost cardiovas-
cular adverse events have been reported [26] and the BRiTE study [22] also 
mentions the occurrence of hypertension as a possible side effect of pro-
longed bevacizumab administration. 
In conclusion, patients with mCRC who experienced disease progression af-
ter first-line treatment have a poor prognosis and the use of bevacizumab in 
maintenance therapy adds to the armamentarium of available treatment op-
tions. However, modest clinical benefits and high treatment costs have to be 
weighed against each other. Future research is required to evaluate optimal 
treatment line(s), dosage and further treatment combinations, as are investi-
gations into EGFR and various VEGF inhibitors for this indication.  
 
 
 
side effects of long-term 
therapy are unknown 
a feasible treatment 
option despite modest 
clinical benefits and 
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